Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. For patients who are not healed after 8 weeks, a subsequent 8-week course may be considered.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. Doses of 20 mg orally once daily may be adequate for some patients.
* **Pathological hypersecretory conditions:** Starting dose is 40 mg orally or intravenously twice daily. Doses may be increased to 80 mg orally or intravenously every 8 hours. The maximum recommended daily dose is 240 mg.
## Pediatric Dosing
* **Erosive esophagitis (12 years and older):** 40 mg orally once daily for 4 to 8 weeks.
* Dosing for younger pediatric patients is not well established and should be based on clinical judgment and available evidence.
## Dose Adjustments
* No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
* In patients with severe hepatic impairment, a maximum dose of 20 mg orally once daily is recommended.
* No dose adjustment is necessary for renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Antiretrovirals:** Pantoprazole can decrease the absorption of antiretrovirals (e.g., atazanavir, nelfinavir). Avoid concomitant use.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider interrupting pantoprazole during methotrexate treatment, especially at high doses.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution is advised when used with other drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, seizures, tetany, arrhythmias).
* Monitor for signs of bone fractures, particularly in patients with risk factors.
* Monitor for signs of vitamin B12 deficiency.
## Clinical Pearls
* Administer oral pantoprazole at least 30 minutes before a meal.
* Intravenous pantoprazole is a potential alternative when oral administration is not feasible.
* The risk of adverse effects, particularly bone fractures and *C. difficile* infection, may increase with prolonged duration of use. Consider the shortest effective duration.
***
**Disclaimer:** This information is intended for clinical use and does not replace comprehensive drug information resources. Always consult the current prescribing information and relevant clinical guidelines before initiating or modifying therapy.
